Abiomed Showcases Impella® Technology that Enables Heart Recovery at ACC with 25 Presentations
March 05 2018 - 8:00AM
Abiomed, Inc. (NASDAQ:ABMD), a leading provider of breakthrough
heart support and recovery technologies, announces that there are
more than 25 presentations scheduled featuring Impella® heart pumps
at the 67th Annual Scientific Session of the American College of
Cardiology (ACC), held March 10-12, 2018, at the Orange County
Convention Center in Orlando, FL.
Impella heart pumps enable treatment and heart recovery for the
growing high risk population of heart failure patients with
advanced coronary artery disease. Abiomed has achieved multiple FDA
PMA approvals, deeming Impella heart pumps safe and effective for
Protected PCI for surgically turned-down complex patients,
cardiogenic shock for emergency patients and for right heart
failure with the Impella RP® heart pump. Abiomed is committed to
advancing the science of heart recovery through technology,
innovation, education and clinical research.
The following initiatives are planned for ACC:
- Abiomed Booth Activities Abiomed's booth #2635
will feature clinical data, demonstrations and opportunities for
physicians to engage in hands-on simulations of the Impella
platform with its augmented reality simulation tool, which allows
physicians to experience the use of hemodynamic support with the
Impella CP® and Impella RP® heart pumps. This is a unique training
tool for insertion, placement and management of the Impella
platform.
- Expanded U.S. FDA PMA Indications for High Risk PCI and
Cardiogenic ShockAbiomed will highlight two recently
expanded U.S. FDA PMA labels. The first expansion is for the
Impella 2.5®, Impella CP®, Impella 5.0® and Impella LD® heart pumps
to provide treatment for heart failure associated with
cardiomyopathy leading to cardiogenic shock. This approval expands
the previous FDA indication for acute myocardial infarction (AMI)
cardiogenic shock and post-cardiotomy cardiogenic shock (PCCS),
received in April 2016. The second expansion is for the Impella
2.5® and Impella
CP® heart pumps during elective and urgent
high risk PCI procedures. This expanded indication confirms Impella
support as appropriate in patients with severe coronary artery
disease, complex anatomy and extensive comorbidities, with or
without depressed ejection fraction.
- Evening Program: The Interventional Toolbox for
Complete Revascularization in Higher-Risk (and Indicated) Patients
(CHIP)This evening program will be held on Friday, March 9
from 6:00-9:00 PM in the Hilton Orlando’s Orange Ballroom D and
will highlight the latest updates on complex PCI. Presentations
will address treatment of patients with complex lesions, including
left main coronary artery disease, chronic total occlusions and
severe calcification. During this interactive session, faculty will
offer insights into selecting appropriate patients for coronary
revascularization and optimizing technique.
- ProtectedPCI.com Digital Community Abiomed's
digital community is the largest source of educational resources on
the Impella platform of devices. Materials available include
protocols and algorithms for appropriate use, summaries on the
latest clinical publications and studies, case recordings and
updates from ACC 2018. Learn more and sign up for updates at
www.protectedpci.com.
- Potential Live Cases Utilizing Impella Devices
Abiomed anticipates the potential broadcast of several elective
live cases utilizing Impella devices from participating sites
during the conference. Further details regarding these live cases
will be announced the day of the scheduled procedures as patient
status is subject to change.
For more information about Abiomed and heart recovery, visit
www.abiomed.com.
ABOUT IMPELLA HEART PUMPS
The Impella 2.5®, Impella CP®, Impella 5.0® and Impella LD® are
FDA-approved heart pumps used to treat heart attack or
cardiomyopathy patients in cardiogenic shock, and have the unique
ability to enable native heart recovery, allowing patients to
return home with their own heart. The Impella 2.5 and Impella CP
devices are also approved to treat certain advanced heart failure
patients undergoing elective and urgent percutaneous coronary
interventions (PCI) such as stenting or balloon angioplasty, to
re-open blocked coronary arteries. Abiomed's right-side heart pump,
the Impella RP® device, is FDA approved to treat patients
experiencing acute right heart failure or decompensation following
left ventricular assist device implantation, myocardial infarction,
heart transplant, or open-heart surgery.
To learn more about the Impella platform of heart pumps,
including their approved indications and important safety and risk
information associated with the use of the devices, please visit:
www.protectedpci.com.
The ABIOMED logo, ABIOMED, Impella, Impella 2.5, Impella 5.0,
Impella LD, Impella CP, Impella RP, and Recovering Hearts. Saving
Lives. are registered trademarks of ABIOMED, Inc. in the U.S. and
in certain foreign countries.
ABOUT ABIOMED
Based in Danvers, Massachusetts, Abiomed, Inc. is a leading
provider of medical devices that provide circulatory support. Our
products are designed to enable the heart to rest by improving
blood flow and/or performing the pumping of the heart. For
additional information, please visit: www.abiomed.com.
For further information please contact:
Ingrid Goldberg Ward Director, Investor Relations 978-646-1590
igoldberg@abiomed.com
FORWARD-LOOKING STATEMENTS
This release contains forward-looking statements, including
statements regarding development of Abiomed's existing and new
products, the Company's progress toward commercial growth, and
future opportunities and expected regulatory approvals. The
Company's actual results may differ materially from those
anticipated in these forward-looking statements based upon a number
of factors, including uncertainties associated with development,
testing and related regulatory approvals, including the potential
for future losses, complex manufacturing, high quality
requirements, dependence on limited sources of supply, competition,
technological change, government regulation, litigation matters,
future capital needs and uncertainty of additional financing, and
other risks and challenges detailed in the Company's filings with
the Securities and Exchange Commission, including the most recently
filed Annual Report on Form 10-K and Quarterly Report on Form 10-Q.
Readers are cautioned not to place undue reliance on any
forward-looking statements, which speak only as of the date of this
release. The Company undertakes no obligation to publicly release
the results of any revisions to these forward-looking statements
that may be made to reflect events or circumstances that occur
after the date of this release or to reflect the occurrence of
unanticipated events.
ABIOMED (NASDAQ:ABMD)
Historical Stock Chart
From Mar 2024 to Apr 2024
ABIOMED (NASDAQ:ABMD)
Historical Stock Chart
From Apr 2023 to Apr 2024